Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$113.18 USD
+0.89 (0.79%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $113.18 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Gilead Sciences, Inc. has a PEG ratio of 0.73 compared to the Medical - Biomedical and Genetics industry's PEG ratio of 1.85.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
GILD 113.18 +0.89(0.79%)
Will GILD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GILD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GILD
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Should You Buy?
Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?
GILD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts
Top Research Reports for NVIDIA, Netflix & Goldman Sachs
Here's Why Gilead Sciences (GILD) is a Strong Value Stock
Other News for GILD
ClearBridge Value Portfolios Q2 2025 Commentary
Market Voices: Trump vs. Big Pharma, Swiss tariffs, tariff legality
Gilead Sciences (GILD) Linked to False Rumors Affecting Pheton Holdings
Trump Trade: Trump signs executive order raising tariff on Canada to 35%
Pheton denies any involvement in 'any form of stock price manipulation'